Senores Pharmaceuticals Ltd Stock Price Today (NSE: SENORES)
Fundamental Score
Senores Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Senores Pharmaceuticals Ltd share price today is ₹1342.60, up +1.06% on NSE/BSE as of 7 August 2026. Senores Pharmaceuticals Ltd (SENORES) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.83K (Cr). The 52-week high for SENORES share price is ₹1509.80 and the 52-week low is ₹632.05. At a P/E ratio of 59.18x, SENORES is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.42% and a debt-to-equity ratio of 0.37.
Senores Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Senores Pharmaceuticals Ltd share price chart: -0.56% return over the past month. 52-week high ₹1509.80, 52-week low ₹632.05.
Senores Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1328.50 | ₹1359.90 | ₹1310.00 | ₹1342.60 | 2.18L (Cr) | |
| ₹1335.00 | ₹1345.60 | ₹1324.00 | ₹1328.50 | 90.23K (Cr) | |
| ₹1371.50 | ₹1374.00 | ₹1306.10 | ₹1323.30 | 4.32L (Cr) | |
| ₹1369.00 | ₹1370.00 | ₹1344.00 | ₹1360.50 | 1.04L (Cr) | |
| ₹1326.60 | ₹1364.40 | ₹1312.10 | ₹1355.30 | 1.99L (Cr) | |
| ₹1298.90 | ₹1329.90 | ₹1293.60 | ₹1305.70 | 1.55L (Cr) | |
| ₹1339.00 | ₹1344.50 | ₹1310.00 | ₹1318.30 | 2.19L (Cr) | |
| ₹1408.30 | ₹1414.80 | ₹1287.90 | ₹1323.90 | 11.65L (Cr) | |
| ₹1408.30 | ₹1443.70 | ₹1378.00 | ₹1412.00 | 4.22L (Cr) | |
| ₹1385.00 | ₹1410.00 | ₹1368.70 | ₹1404.00 | 1.31L (Cr) |
Senores Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1326.60 | ₹1374.00 | ₹1306.10 | ₹1342.60 | +1.21% | |
| ₹1343.40 | ₹1509.80 | ₹1287.90 | ₹1305.70 | -2.81% | |
| ₹1042.30 | ₹1360.00 | ₹1001.00 | ₹1329.90 | +27.59% | |
| ₹904.00 | ₹1194.40 | ₹877.55 | ₹1120.65 | +23.97% | |
| ₹797.00 | ₹947.70 | ₹741.90 | ₹899.20 | +12.82% | |
| ₹747.00 | ₹801.40 | ₹706.00 | ₹759.60 | +1.69% | |
| ₹786.00 | ₹849.40 | ₹760.00 | ₹764.90 | -2.68% | |
| ₹825.00 | ₹876.50 | ₹752.40 | ₹787.95 | -4.49% | |
| ₹825.00 | ₹849.10 | ₹738.10 | ₹822.20 | -0.34% | |
| ₹771.20 | ₹832.00 | ₹755.00 | ₹823.70 | +6.81% | |
| ₹689.95 | ₹790.00 | ₹684.60 | ₹771.20 | +11.78% | |
| ₹690.15 | ₹751.20 | ₹662.45 | ₹688.10 | -0.30% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Senores Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Senores Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SENORES across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Excellent ROCE Performance (15.13%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.27%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (77.29%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (53.39%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (7.36x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 59.18x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-552.97 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Senores Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Senores Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Senores Pharmaceuticals LtdSenores Pharmac...Selected✓ SENORES • 544319 | 44.7/100 | ₹1342.60₹1343 | ₹6826.66₹6826.66 | 59.18Average 59.2 Average | 13.42%Average 13.42% Average | 15.13%Good 15.13% Good | 0.37Excellent 0.4 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Senores Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for SENORES — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹16.12 | ₹822.20 | 51x |
| FY 2024 | ₹6.83 | ₹568.60 | 83.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Senores Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for SENORES — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
53.39%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
77.29%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Senores Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SENORES — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Senores Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Senores Pharmaceuticals Ltd (SENORES) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Senores Pharmaceuticals Ltd
About SENORES (Senores Pharmaceuticals Ltd)
Senores Pharmaceuticals Ltd is a global pharmaceutical company dedicated to advancing healthcare through the discovery, development, and commercialization of innovative therapies. ...With a strong emphasis on research and development, Senores Pharmaceuticals is committed to addressing unmet medical needs across a broad range of therapeutic areas. The company's mission is to improve patient outcomes and enhance the quality of life for individuals worldwide by providing access to safe, effective, and affordable medicines. Senores Pharmaceuticals operates with the highest ethical standards and a focus on sustainability, ensuring that its business practices are environmentally responsible and socially conscious. They strive to be a trusted partner for healthcare professionals and patients, offering comprehensive support and resources to optimize treatment outcomes. Driven by a passion for scientific excellence, Senores Pharmaceuticals invests heavily in cutting-edge technologies and strategic collaborations to accelerate the development of novel therapeutics. The company's robust pipeline includes a diverse portfolio of products in various stages of development, targeting diseases with significant unmet needs. Senores Pharmaceuticals is committed to bringing innovative solutions to market that transform the lives of patients. Their experienced team of scientists, clinicians, and business professionals work collaboratively to navigate the complex regulatory landscape and ensure the timely delivery of high-quality products to patients in need. Senores Pharmaceuticals is dedicated to fostering a culture of innovation, collaboration, and patient-centricity, where every employee is empowered to make a difference in the world. Senores Pharmaceuticals is focused on expanding its global reach and strengthening its presence in key markets. The company's commercial operations are supported by a dedicated sales and marketing team that is committed to providing healthcare professionals with the information and resources they need to make informed treatment decisions. Senores Pharmaceuticals has established a strong distribution network to ensure that its products are readily available to patients around the world. In addition to its own product portfolio, Senores Pharmaceuticals is actively seeking partnerships and licensing agreements to expand its offerings and address a wider range of medical needs. The company is dedicated to building long-term relationships with healthcare providers, payers, and patient advocacy groups to improve access to care and promote positive health outcomes.
Company Details
Key Leadership
SENORES Share Price: Frequently Asked Questions
What is the current share price of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd (SENORES) trades at ₹1342.60 on NSE and BSE. Market cap ₹6.83K (Cr). Educational data only.
What is the P/E ratio of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has a P/E of 59.18x vs industry average 34.89x.
What is the Bull Run score for Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has a Bull Run score of 44.7/100 based on 25+ financial parameters.
Does Senores Pharmaceuticals Ltd pay dividends?
Senores Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has ROE of 13.42%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has debt-to-equity of 0.37.
Is Senores Pharmaceuticals Ltd a good investment?
Bull Run gives Senores Pharmaceuticals Ltd a score of 44.7/100. This is not investment advice — consult a SEBI-registered advisor.